FDA Approves First PROTAC Drug VEPPANU for ESR1-Mutated Breast Cancer
核心洞察
The FDA has approved VEPPANU (搜索) (vepdegestrant), marking the first-ever approval of a PROTAC protein degrader therapy for treating ESR1 (搜索)-mutated, ER+/HER2- advanced breast cancer.
The approval was based on VERITAC-2 Phase 3 trial results showing a 43% reduction in disease progression risk compared to fulvestrant, with median progression-free survival of 5 months versus 2.1 months.
VEPPANU (搜索) addresses a significant unmet medical need for patients with endocrine-resistant breast cancer, where up to 40-50% develop ESR1 (搜索) mutations after CDK4/6 inhibitor treatment.
The U.S. Food and Drug Administration has granted approval for VEPPANU (搜索) (vepdegestrant), marking a historic milestone as the first PROteolysis TArgeting Chimera (PROTAC) therapy to receive regulatory approval. Developed jointly by Arvinas and Pfizer, VEPPANU is indicated for adults with estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-), ESR1 (搜索)-mutated advanced or metastatic breast cancer who have experienced disease progression following at least one line of endocrine therapy.
Breakthrough PROTAC Technology
"Today's FDA approval is a transformative moment for Arvinas as we achieve our first approved medicine and the first-ever approved PROTAC therapy based on the technology we've pioneered since 2013," said Randy Teel, Ph.D., President and Chief Executive Officer at Arvinas. The approval represents the culmination of research that originated at Yale University (搜索), where Professor Craig Crews, Ph.D., co-authored the first-ever paper on PROTAC protein degraders.
PROTAC technology represents a novel therapeutic approach that harnesses the body's natural protein disposal system to selectively degrade disease-causing proteins. Unlike traditional small molecule inhibitors that block protein function, PROTAC degraders eliminate the target protein entirely, potentially offering advantages in overcoming resistance mechanisms.
Addressing Critical Unmet Need
The approval addresses a significant gap in treatment options for patients with ESR1 (搜索)-mutated breast cancer. While endocrine therapy remains a cornerstone of metastatic ER+/HER2- breast cancer treatment, up to 40-50% of patients treated with endocrine therapy and a CDK4/6 inhibitor develop ESR1 mutations, resulting in endocrine resistance and poor prognosis. These patients often experience rapid disease progression and face limited options after first-line therapy.
"For patients living with ESR1 (搜索) mutant, ER+/HER2 advanced breast cancer, there have been minimal second-line treatment options once standard therapies are no longer effective," said Erika Hamilton, M.D., Chief Development Officer, Late Phase, and Director, Breast Cancer Research, Sarah Cannon Research Institute (搜索), who served as a principal investigator of the VERITAC-2 trial. "The introduction of a new, targeted treatment is an encouraging development for this community and highlights meaningful innovation in the way this disease is treated."
Robust Clinical Evidence
FDA approval was granted based on data from VERITAC-2 (NCT05654623), a global, randomized, open-label, pivotal Phase 3 clinical trial that enrolled 624 patients at 213 sites across 25 countries. The trial evaluated vepdegestrant versus fulvestrant in patients with ER+/HER2- advanced or metastatic breast cancer previously treated with a CDK4/6 inhibitor plus endocrine therapy.
Among the 270 patients with ESR1 (搜索) mutations, vepdegestrant demonstrated statistically significant and clinically meaningful improvement in progression-free survival (PFS). The treatment reduced the risk of disease progression or death by 43% compared to fulvestrant, with a median PFS of 5 months (95% CI: 3.7, 7.4) versus 2.1 months (95% CI: 1.9, 3.5) for fulvestrant (hazard ratio 0.57 [95% CI: 0.42, 0.77]; p-value 0.0001).
Safety Profile and Administration
The majority of adverse events with vepdegestrant were low grade (Grade 1-2). The most common adverse reactions (≥10%) included decreased white blood cells, increased AST, musculoskeletal pain, fatigue, decreased hemoglobin, decreased neutrophils, increased ALT, increased alkaline phosphatase, nausea, decreased blood potassium, increased bilirubin, decreased appetite, electrocardiogram QT prolonged, decreased platelets, and constipation.
VEPPANU (搜索) offers practical advantages as an oral therapy administered once daily on a 28-day continuous dosing schedule, compared to fulvestrant's intramuscular injection regimen. "Today's approval provides a new oral treatment option that showed improved progression free survival when compared to the current standard of care, fulvestrant, which is administered via an intramuscular injection," noted Noah Berkowitz, M.D., Ph.D., Chief Medical Officer at Arvinas.
Commercial Strategy and Future Outlook
The approval came ahead of the FDA-assigned PDUFA date of June 5, 2026, demonstrating the agency's recognition of the drug's clinical significance. Arvinas and Pfizer plan to jointly identify and select a third-party partner with the capabilities and expertise to maximize VEPPANU (搜索)'s commercial potential, with the companies on track to announce their selection.
Beyond VEPPANU (搜索), Arvinas is advancing multiple investigational PROTAC degraders through clinical development, including ARV-102 targeting LRRK2 (搜索) for neurodegenerative disorders, ARV-806 (搜索) targeting KRAS G12D (搜索) for mutated cancers, ARV-393 targeting BCL6 for relapsed/refractory non-Hodgkin lymphoma, and ARV-027 (搜索) targeting polyglutamine-expanded androgen receptor in skeletal muscle.
The approval establishes PROTAC technology as a validated therapeutic modality and positions Arvinas at the forefront of protein degradation medicine, with potential applications extending across oncology, neurodegenerative, and neuromuscular diseases.